Given that metformin is safe, cheap and widely used to treat individuals with type 2 diabetes, obesity, and polycystic ovarian syndrome, we propose that metformin has potentially marked clinical utility in the future, since ILD events are an important consideration in the development of EGFR-TKIs. Here, EGFR is linked to type 2 diabetes mellitus.